Get the Stockscreener App
2.355
3.09%
-0.075
Maxcyte Inc stock is traded at $2.355, with a volume of 1.94M.
It is down -3.09% in the last 24 hours and down -6.92% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$2.43
Open:
$2.43
24h Volume:
1.94M
Relative Volume:
2.90
Market Cap:
$299.80M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-6.9265
EPS:
-0.34
Net Cash Flow:
$-25.39M
1W Performance:
-16.49%
1M Performance:
-6.92%
6M Performance:
-30.43%
1Y Performance:
-50.21%
1-Day Range:
$2.29
$2.43
1-Week Range:
$2.29
$2.86
52-Week Range:
$2.21
$5.26
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
2.355 | 299.80M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
MaxCyte Files Form 10-Q for Q1 2025 - TipRanks
BTIG cuts MaxCyte stock price target to $5, maintains Buy rating - Investing.com
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates - MSN
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know - MSN
Earnings call transcript: MaxCyte Q1 2025 beats revenue forecast, stock reacts - Investing.com
Wells Fargo & Company MN Boosts Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MaxCyte Reports Q1 2025 Financial Results Amid Revenue Dip - TipRanks
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance - The Manila Times
MaxCyte reports Q1 EPS (10c), consensus (10c) - TipRanks
Financial Fitness Check: Examining MaxCyte Inc (MXCT)’s Key Ratios - DWinneX
A Look at MaxCyte's Upcoming Earnings Report - Nasdaq
MaxCyte Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Invesco Ltd. Has $204,000 Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte (MXCT) to Release Quarterly Earnings on Wednesday - Defense World
MaxCyte, Inc. (NASDAQ:MXCT) Position Trimmed by Legal & General Group Plc - Defense World
MaxCyte Expands Stock Capital with New Share Issuance - TipRanks
Upward Trajectory: MaxCyte Inc (MXCT) Posts a Slidee, Closing at 2.84 - DWinneX
A stock that deserves closer examination: MaxCyte Inc (MXCT) - uspostnews.com
Renaissance Technologies LLC Has $1.17 Million Stock Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by JPMorgan Chase & Co. - Defense World
MaxCyte Announces AIM Delisting to Focus on NASDAQ - TipRanks
MaxCyte Inc (MXCT) requires closer examination - uspostnews.com
BlackRock Adjusts Stake in MaxCyte, Inc. - TipRanks
MaxCyte Announces Change in Major Shareholder Holdings - TipRanks
Vanguard Group Inc. Sells 345,587 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
Cooley Advises Cell Therapy Biz On London Market Exit - Law360
MaxCyte intends to delist from London's AIM to enhance liquidity - marketscreener.com
MaxCyte to Delist from AIM, Focus on Nasdaq - TipRanks
MaxCyte Announces Change in Voting Rights Structure - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Stock Holdings Lifted by American Century Companies Inc. - Defense World
MaxCyte stock plunges to 52-week low of $2.25 amid market challenges By Investing.com - Investing.com South Africa
MaxCyte stock plunges to 52-week low of $2.25 amid market challenges - Investing.com India
MaxCyte sets date for Q1 2025 financial results reveal By Investing.com - Investing.com South Africa
MaxCyte sets date for Q1 2025 financial results reveal - Investing.com
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - The Manila Times
MaxCyte to Announce Q1 2025 Financial Results - TipRanks
Insider Buyers Lose US$201k As MaxCyte Sheds UK£32m - simplywall.st
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) - Yahoo Finance
With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns - Yahoo Finance
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround - Yahoo Finance
MaxCyte Inc (MXCT) Volatility Hits 6.24% – Here Is What You Should Do - Stocksregister
MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges - Investing.com Australia
MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges By Investing.com - Investing.com South Africa
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maxcyte Inc Stock (MXCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sandoval David I. | GENERAL COUNSEL |
Mar 18 '25 |
Sale |
3.18 |
353 |
1,122 |
64,219 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Mar 18 '25 |
Sale |
3.18 |
6,939 |
22,061 |
111,811 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Sale |
4.64 |
3,000 |
13,935 |
141,950 |
| Sandoval David I. | GENERAL COUNSEL |
Jan 13 '25 |
Sale |
4.54 |
4,466 |
20,272 |
41,447 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Sale |
4.01 |
3,000 |
12,021 |
141,950 |
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):